Feed RAPP
RA

Rapport Therapeutics, Inc. Common Stock

RAPP · NASDAQ

$40.45 -5.93% (-$2.55)
1M -18.00%
Market Cap $2.01B
P/E Ratio -
Div. Yield -
ROE 29.02%
Piotroski F-Score Weak
2/9
Valuation
21 /100
Expensive
P/S 100.32x
P/B 4.74x
P/E N/A
Growth
100 /100
Growing
Book val. growth 191.81%
EPS growth N/A
Rev. growth N/A
Profitability
20 /100
Weak
Gross margin 100.00%
Net margin 685.80%
FCF margin 485.75%
Quality
1 /100
Poor
ROIC 35.45%
ROE 29.02%
Asset turnover 0.04x
Debt
100 /100
Low
Debt/Equity 0.02x
Current ratio 15.72x
Int. coverage N/A
Stability
31 /100
Unstable
Beta 1.03x
EPS volatility 169.43%
Profitable years 0

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about RAPP
Online

Sector

Healthcare

Industry

Biotechnology

CEO

Abraham N. Ceesay

Employees

84

Headquarters

Boston

Upcoming events

05 NOV

Earnings

Upcoming earnings report

45d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.